Perioperative chemotherapy for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Authors :: Al-Batran, Salah-Eddin
Homann, Nils
Pauligk, Claudia
Goetze, Thorsten O
Meiler, Johannes
Kasper, Stefan
Kopp, Hans-Georg
Mayer, Frank
Haag, Georg Martin
Luley, Kim
Lindig, Udo
Schmiegel, Wolff
Pohl, Michael
Stoehlmacher, Jan
Folprecht, Gunnar
Probst, Stephan
Prasnikar, Nicole
Fischbach, Wolfgang
Mahlberg, Rolf
Trojan, Jörg
Koenigsmann, Michael
Martens, Uwe M
Thuss-Patience, Peter
Egger, Matthias
Block, Andreas
Heinemann, Volker
Illerhaus, Gerald
Moehler, Markus
Schenk, Michael
Kullmann, Frank
Behringer, Dirk M
Heike, Michael
Pink, Daniel
Teschendorf, Christian
Löhr, Carmen
Bernhard, Helga
Schuch, Gunter
Rethwisch, Volker
von Weikersthal, Ludwig Fischer
Hartmann, Jörg T
Kneba, Michael
Daum, Severin
Schulmann, Karsten
Weniger, Jörg
Belle, Sebastian
Gaiser, Timo
Oduncu, Fuat S
Güntner, Martina
Hozaeel, Wael
Reichart, Alexander
Jäger, Elke
Kraus, Thomas
Moenig, Stefan Paul
Bechstein, Wolf O
Schuler, Martin
Schmalenberg, Harald
Hofheinz, Ralf D
FLOT4-AIO Investigators
Source :: The Lancet, Vol. 393, No 10184 (2019) pp. 1948-1957
Publication Year :: 2019
Abstract: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel) as a perioperative therapy for patients with locally advanced, resectable tumours.

Tools